November 2013 PBAC Meeting Outcomes - Review Drug and Form Drug use and type Purpose of Review PBAC Recommendation CINACALCET, 30 mg, 60 mg and 90 mg, tablet Senisipar® - Amgen - Document - PDFSEARCH.IO

First Page	Meta Content
	November 2013 PBAC Meeting Outcomes - Review Drug and Form Drug use and type Purpose of Review PBAC Recommendation CINACALCET, 30 mg, 60 mg and 90 mg, tablet Senisipar® Add to Reading List Document Date: 2015-01-19 17:21:09 Open Document File Size: 36,00 KB Share Result on Facebook Company Amgen Australia Pty Ltd / / Currency USD / / IndustryTerm revised utilities / clinical management algorithm / / MedicalCondition end stage renal disease / hyperparathyroidism / secondary hyperparathyroidism / / MedicalTreatment dialysis / / Organization Economics Subcommittee / / Product Senisipar / / Technology clinical management algorithm / dialysis / / SocialTag Clinical research Science Drugs Cinacalcet Secondary hyperparathyroidism Clinical trial Amgen Placebo Hyperparathyroidism Medicine

November 2013 PBAC Meeting Outcomes - Review Drug and Form Drug use and type Purpose of Review PBAC Recommendation CINACALCET, 30 mg, 60 mg and 90 mg, tablet Senisipar®Add to Reading List